40) mL/min/1.73m2 (returning toward baseline during washout) and by -0.78 (95% CI -2.22 to 0.66) mL/min/1.73m2 with placebo (difference -1.99 (95% CI -3.97 to -0.01); p=0.049).AEs were consistent with the established safety profile for finerenone.Hyperkalemia was more common with finerenone compared with placebo (n=12 10.1% vs n=4 3.3%); however, discontinuations (n=2 1.7% vs n=0) and hospitalizations (n=2 1.7% vs n=0) were uncommon.AE incidence was generally not modified by the finerenoneassociated change in eGFR at Month 1. Conclusion:In FINE-ONE, finerenone reduced UACR compared with placebo over 6 months of treatment and had a tolerable safety profile in patients with CKD and T1D.These results imply that finerenone may afford long-term benefits in patients with T1D and CKD.Part of these data were previously presented at the American Society of Nephrology 2025 congress.I have potential conflict of interest to disclose.
Alon Yaar (Wed,) studied this question.